EVOGENE LTD (EVGN)
IL0011050551 - Common Stock
Taking everything into account, EVGN scores 2 out of 10 in our fundamental rating. EVGN was compared to 565 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year EVGN has reported negative net income.
In the past year EVGN has reported a negative cash flow from operations.
EVGN had negative earnings in each of the past 5 years.
EVGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
EVGN's Return On Assets of -58.62% is in line compared to the rest of the industry. EVGN outperforms 41.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.62% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 68.90%, EVGN belongs to the best of the industry, outperforming 82.56% of the companies in the same industry.
EVGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVGN has less shares outstanding
The number of shares outstanding for EVGN has been reduced compared to 5 years ago.
Compared to 1 year ago, EVGN has a worse debt to assets ratio.
2.2 Solvency
EVGN has an Altman-Z score of -11.28. This is a bad value and indicates that EVGN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.28, EVGN is doing worse than 76.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.28 |
ROIC/WACCN/A
WACC5.84%
2.3 Liquidity
A Current Ratio of 1.09 indicates that EVGN should not have too much problems paying its short term obligations.
With a Current ratio value of 1.09, EVGN is not doing good in the industry: 86.83% of the companies in the same industry are doing better.
A Quick Ratio of 1.03 indicates that EVGN should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.03, EVGN is not doing good in the industry: 86.65% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.89% over the past year.
EVGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.80%.
The Revenue has been growing by 26.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.75%
Revenue 1Y (TTM)30.8%
Revenue growth 3Y75.69%
Revenue growth 5Y26.37%
Sales Q2Q%-52.32%
3.2 Future
EVGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.39% yearly.
EVGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.38% yearly.
EPS Next Y20.81%
EPS Next 2Y18.38%
EPS Next 3Y16.39%
EPS Next 5YN/A
Revenue Next Year89.65%
Revenue Next 2Y62.19%
Revenue Next 3Y67.38%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EVGN's earnings are expected to grow with 16.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.38%
EPS Next 3Y16.39%
5. Dividend
5.1 Amount
EVGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOGENE LTD
NASDAQ:EVGN (12/23/2024, 11:38:38 AM)
1.405
+0.05 (+4.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.96%
Inst Owner Change-15.35%
Ins Owners1.66%
Ins Owner ChangeN/A
Market Cap7.11M
Analysts82.5
Price Target8.29 (490.04%)
Short Float %1.65%
Short Ratio0.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.15%
Min EPS beat(2)-27.16%
Max EPS beat(2)16.86%
EPS beat(4)3
Avg EPS beat(4)4.03%
Min EPS beat(4)-27.16%
Max EPS beat(4)17.44%
EPS beat(8)7
Avg EPS beat(8)18.07%
EPS beat(12)9
Avg EPS beat(12)12.8%
EPS beat(16)11
Avg EPS beat(16)7.85%
Revenue beat(2)1
Avg Revenue beat(2)-13.1%
Min Revenue beat(2)-38.22%
Max Revenue beat(2)12.01%
Revenue beat(4)3
Avg Revenue beat(4)1.12%
Min Revenue beat(4)-38.22%
Max Revenue beat(4)17.37%
Revenue beat(8)5
Avg Revenue beat(8)26.79%
Revenue beat(12)8
Avg Revenue beat(12)67.45%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-39.81%
PT rev (3m)-52.9%
EPS NQ rev (1m)-21.31%
EPS NQ rev (3m)-543.48%
EPS NY rev (1m)-12.89%
EPS NY rev (3m)-12.89%
Revenue NQ rev (1m)-49.29%
Revenue NQ rev (3m)20.85%
Revenue NY rev (1m)-30.3%
Revenue NY rev (3m)-30.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.47
EYN/A
EPS(NY)-3.17
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4.04
OCFYN/A
SpS1.48
BVpS-0.86
TBVpS-3.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.62% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.9% | ||
| FCFM | N/A |
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.15% | ||
| Cap/Sales | 5.22% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | -11.28 |
F-Score3
WACC5.84%
ROIC/WACCN/A
Cap/Depr(3y)37.84%
Cap/Depr(5y)34.18%
Cap/Sales(3y)58.32%
Cap/Sales(5y)72.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.75%
EPS Next Y20.81%
EPS Next 2Y18.38%
EPS Next 3Y16.39%
EPS Next 5YN/A
Revenue 1Y (TTM)30.8%
Revenue growth 3Y75.69%
Revenue growth 5Y26.37%
Sales Q2Q%-52.32%
Revenue Next Year89.65%
Revenue Next 2Y62.19%
Revenue Next 3Y67.38%
Revenue Next 5YN/A
EBIT growth 1Y5.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.23%
EBIT Next 3Y19.45%
EBIT Next 5YN/A
FCF growth 1Y32.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.81%
OCF growth 3YN/A
OCF growth 5YN/A